New Analyst Forecast: $BRKR Given 'Neutral' Rating
Bruker to Launch Beacon Discovery at AACR 2025, Expanding Access to Live Single-Cell Functional Analysis
Solis Agrosciences Names Crystal Winkeler Chief Business Officer to Drive Commercial Growth
Wells Fargo Maintains Bruker Corp(BRKR.US) With Buy Rating, Cuts Target Price to $60
Bruker Corporation (BRKR): Among Mid-Cap Stocks Insiders Were Buying in Q1 2025
A Glimpse Into The Expert Outlook On Bruker Through 6 Analysts
Bruker Is Maintained at Overweight by Wells Fargo
Bruker Analyst Ratings
Express News | Bruker Corporation : Wells Fargo Cuts Target Price to $60 From $75
Bruker Introduces NVista 2P Miniature Microscope
Bruker Acquires Majority Stake in RECIPE Chemicals
Express News | Bruker Corp - Financial Details of Transaction Were Not Disclosed
Press Release: Bruker Announces Majority Acquisition of RECIPE, a Leading Provider of Mass Spectrometry-based Diagnostic Assay Kits for Therapeutic Drug Monitoring
Bruker Announces Majority Acquisition Of RECIPE, A Leading Provider Of Mass Spectrometry-based Diagnostic Assay Kits For Therapeutic Drug Monitoring >BRKR
Google is facing a lawsuit of 5 billion British Pounds in the United Kingdom for abusing its "near-monopoly status" in the search market.
Google is facing potential compensation lawsuits of over 5 billion British Pound (approximately 6.6 billion USD) in the United Kingdom, accused of abusing its "near monopoly position" in the online search market to inflate advertising prices. The class action lawsuit, filed on Wednesday (April 17) in the UK Competition Appeal Tribunal, claims that Google consolidated its market dominance by limiting competitor Search Engines, making itself the only viable option for online search advertising. The lawsuit was filed by competition law scholar O. Bruker on behalf of hundreds of thousands of UK Institutions that used Google Advertising Services from January 1, 2011, to the time of the lawsuit. Bruker stated on Tuesday.
Life Sciences Companies Likely to See Surprisingly Good 1Q Results -- Market Talk
BofA Securities Lowers Bruker Price Target to $61 From $76
Barclays Maintains Bruker Corp(BRKR.US) With Buy Rating, Maintains Target Price $50
Barclays Remains a Buy on Bruker (BRKR)
Why Is Life Science Focused Bruker Stock Trading Higher On Friday?